Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Study on Acute Myeloid Leukemia

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 25 May 2026 | Viewed by 11390

Share This Special Issue

Special Issue Editor

Dr. Olga K. Weinberg

E-Mail Website
Guest Editor

Division of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Interests: AML; myeloid neoplasms; biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow, and is characterized by the rapid growth of abnormal white blood cells. The strategies employed to treat AML are developing, with chemotherapy and other therapies being utilized. AML occurs due to mutations in the hematopoietic stem cells, leading to an uncontrolled proliferation of immature blood cells. The diagnosis of AML is typically based on blood tests, bone marrow biopsy, and genetic profiling to identify mutations. In summary, this Special Issue will focus on the various treatment modalities employed to address acute myeloid leukemia.

Dr. Olga K. Weinberg
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

acute myeloid leukemia (AML)
cancer treatment
genetic

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

23 pages, 3202 KB

Open AccessArticle

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS)

by Argiris Symeonidis, Panagiotis Diamantopoulos, Athanasios Galanopoulos, Alexandra Kourakli, Eleni Sazakli, Eleftheria Hatzimichael, Maria Pagoni, Panagiotis Zikos, Theodoros P. Vassilakopoulos, Eleni Gavrilaki, Anthi Bouchla, Anna Kioumi, Katerina Palla, Ioannis Kotsianidis, Evridiki Michali, Zafiris Kartassis, Eirini Katodritou, Vasileios Lazaris, Maria Vagia, George Xanthopoulidis, Theodora Assimakopoulou, Charalampos Pontikoglou, Maria Dimou, Maria Dalekou-Tsolakou, Dimitra Liapi, Maria Kotsopoulou, Vassiliki Labropoulou, Menelaos Papoutselis, Despina Barmparousi, Efthymia Vlachaki, Georgia Kaiafa, Eleni Chandrinou, Panagiotis Karmas, Evangelos Terpos, George Vassilopoulos, Panayiotis Panayiotidis, Nora-Athina Viniou and Vassiliki Pappa Show full author list Hide full author list

Cancers 2025, 17(9), 1388; https://doi.org/10.3390/cancers17091388 - 22 Apr 2025

Cited by 4 | Viewed by 3485

Abstract

Background-Objectives: Although considered standard of care for patients with low-/intermediate-1 risk MDS and isolated del(5q), lenalidomide is not widely used in patients exhibiting additional cytogenetic abnormalities, on top of del(5)q. The aim of this study was to provide real-world evidence for the efficacy of lenalidomide in patients with del(5q), with or without additional cytogenetic abnormalities. Methods: Patients with MDS exhibiting del(5q) in the Greek National Myelodysplastic Syndromes Registry were analyzed if they had received at least one lenalidomide dose and detailed response assessment/follow-up was available. Results: Among 238 patients analyzed, 153 (64.3%) had del(5q) syndrome (Group-I), 34 (14.3%) had an isolated del(5q) abnormality but were not 5q− syndrome (Group-II), 26 (10.9%) had del(5q) plus only one additional cytogenetic abnormality (Group-III), and 25 (10.5%) had del(5q) plus >1 additional abnormality (Group-IV). Among 218 (91.6%) evaluable patients, a major response was achieved by 146 (67.0%) patients, 114/146 (78.1%) in Group-I, 18/31 (58.1%) in Group-II, 10/20 (50.0%) in Group-III, and 4/21 (19.0%) in Group-IV. Overall, hematological response was seen in 177/218 (81.2%) patients, even among those with an excess of bone marrow blasts/frank acute myeloid leukemia. Duration of response was comparable between the four patient groups. A complete cytogenetic response was achieved by 38.0% overall, more commonly in Group-I (42.3%) and -III (35.7%). Transfusion-independent patients and those with a higher MCV or lower marrow blast cells at baseline had a higher probability of achieving a major response. With multivariate analysis, factors associated with overall survival were age, performance status, transfusion dependence, and marrow blast cell percentage at treatment start, as well as time from initial diagnosis to lenalidomide start. Conclusions: Lenalidomide was highly effective in patients with the del(5)q syndrome and also in those with isolated del(5)q, other than del(5)q syndrome, or those exhibiting del(5)q plus only one additional cytogenetic abnormality, not affecting chromosome 7. Full article

(This article belongs to the Special Issue Study on Acute Myeloid Leukemia)

► Show Figures

Figure 1

14 pages, 1894 KB

Open AccessArticle

Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases

by Hyung C. Suh, Scott D. Rowley, Sukhdeep Kaur, Brittany Lukasik, Phyllis McKiernan, Michele Boonstra, Melissa Baker, Mary DiLorenzo, Alan Skarbnik, Jason Voss, Alexandra Hampson, Bianca DeAgresta, Brighid Boylan, Themba Nyirenda, David H. Vesole and Michele L. Donato

Cancers 2025, 17(7), 1140; https://doi.org/10.3390/cancers17071140 - 28 Mar 2025

Cited by 2 | Viewed by 1361

Abstract

Background/Objectives: Allogeneic hematopoietic stem cell transplantation (alloSCT) is a curative treatment for myeloid diseases, yet relapse remains the major cause of post-transplant mortality. To reduce the risk of recurrence, we evaluated the addition of 400 cGy total body irradiation (TBI) to conditioning with fludarabine-busulfan (Flu/Bu4). Methods: In this prospective study, 46 patients with myeloid diseases were randomized to Flu/Bu4 or Flu/Bu4/TBI conditioning group. The Flu/Bu4 conditioning regimen consisted of fludarabine 40 mg/m² on days -6 to -3 followed by busulfan 130 mg/m² on days -6 to -3. Flu/Bu4/TBI conditioning regimen added 400 cGy TBI on day -1 to the FluBu4 regimen. Results: Among 34 acute myeloid leukemia (AML) patients, relapse was numerically lower in those who received Flu/Bu4/TBI (25%) versus Flu/Bu4 (44.4%) at three years (HR = 0.58, 95% CI 0.19 to 1.81, p = 0.35). Flu/Bu4/TBI appeared to increase the risk of non-relapse mortality (NRM) vs. Flu/Bu4 in AML patients at three years (25.0% versus 11.1%; HR = 2.11, 95% CI 0.51 to 8.83, p = 0.65). Overall survival (OS) was similar in AML patients undergoing conditioning with Flu/Bu4 (72.2%) versus Flu/Bu4/TBI (62.5%) at one year (p = 0.4). Conclusions: In conclusion, the addition of 400 cGy TBI to Flu/Bu4 reduced the risk of relapse but did not improve OS as a consequence of higher regimen-related mortality. Clinicaltrials.gov identifier: NCT01366612. Full article

(This article belongs to the Special Issue Study on Acute Myeloid Leukemia)

► Show Figures

Figure 1

Review

Jump to: Research

54 pages, 3566 KB

Open AccessReview

Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions

by Faten Merhi, Daniel Dauzonne and Brigitte Bauvois

Cancers 2026, 18(2), 185; https://doi.org/10.3390/cancers18020185 - 6 Jan 2026

Viewed by 1545

Abstract

Bioactive natural products (NPs) may play a critical role in cancer progression by targeting nucleic acids and a wide array of proteins, including enzymes. Furthermore, a large number of derivatives (NPDs), including semi-synthetic products and pharmacophores from NPs, have been developed to enhance the solubility and stability of NPs. Acute myeloid leukemia (AML) is a poor-prognosis hematologic malignancy characterized by the clonal accumulation in the blood and bone marrow of myeloid progenitors with high proliferative capacity, survival and propagation abilities. A number of potential pathways and targets have been identified for development in AML, and include, but are not limited to, Fms-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenases resulting from genetic mutations, BCL2 family members, various signaling kinases and histone deacetylases, as well as tumor-associated antigens (such as CD13, CD33, P-gp). By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. However, the effective treatment of the disease remains challenging, in part due to the heterogeneity of the disease but also to the involvement of the bone marrow microenvironment and the immune system in favoring leukemic stem cell persistence. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism. Full article

(This article belongs to the Special Issue Study on Acute Myeloid Leukemia)

► Show Figures

Figure 1

17 pages, 1452 KB

Open AccessReview

Evolving Paradigms in Acute Myeloid Leukemia: Personalized Approaches to Therapy Across Age and Risk Groups

by Sumeet K. Yadav, Utsav Joshi, Guleid Hussein, Mohamed Warsame, Bolun Liu, Abhash Shrestha, Peter Krastev, Hariprasad Reddy Korsapati and Amrit Singh

Cancers 2025, 17(17), 2824; https://doi.org/10.3390/cancers17172824 - 28 Aug 2025

Cited by 2 | Viewed by 4259

Abstract

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the clonal proliferation of myeloid precursors and rapid progression. Historically consisting of intensive chemotherapy, AML management has evolved significantly due to advances in molecular diagnostics and risk stratification. This review discusses current therapeutic paradigms in AML, emphasizing the growing role of personalized medicine across age and risk groups. For younger, fit patients, intensive regimens such as the “7 + 3” protocol remain the standard, often enhanced by targeted agents like FMS-like tyrosine kinase 3 (FLT3) and IDH inhibitors. Older or unfit individuals benefit from low-intensity treatments such as hypomethylating agents combined with venetoclax, now considered a frontline standard of care. The use of liposomal chemotherapy (CPX-351), measurable residual disease (MRD) monitoring, and maintenance therapy further refine post-remission strategies. Emerging therapies, including menin inhibitors, antibody–drug conjugates, and immunotherapies like CAR-T cells and vaccines, offer additional options, especially in relapsed/refractory settings. This comprehensive review outlines the current landscape and future directions in AML therapy, emphasizing the transition toward individualized, mutation-driven treatment strategies. Full article

(This article belongs to the Special Issue Study on Acute Myeloid Leukemia)

► Show Figures

Journal Menu

Journal Browser

Study on Acute Myeloid Leukemia

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (4 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI